Madrenas_01

By cumulave acute rejecon episodes

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: allogra; mount an alloresponse against the recipient’s cells –  Clinically, this response translates into skin/GI/liver disease –  Generally due to mismatches in class I and/or class II MHC molecules –  Can also be triggered by minor histocompa#bility an#gens •  Most common in bone marrow transplanta#on, rare in solid organ transplanta#on •  Presence of donor’s alloreac#ve T cells against recipient’s cells can be detected by the mixed lymphocyte reac#on (MLR) •  Treated with immunosuppression •  A degree of GVHD is beneficial in BMT for leukemia •  Some donor’s T cells can recognize mHA or tumour- specific an#gens and kill leukemic cells, preven#ng leukemia relapse •  •  •  State in which the allogra; is not recognized as foreign Some#mes occurs spontaneously through unclear mechanisms Natural Model = pregnancy –  Immune privileged site •  ? Lack of recogni#on •  ? HLA- G –  Inducer of an immunosuppressive response •  ?Nutrient deple#on (IDO) •  ?Immunodevia#on: TGF- β, IL-10 •  ?Treg •  •  Intensive search for therapies to induce it Examples: –  –  –  –  –  Thymectomy Donor cell injec#on Stem cell transplanta#on Bone marrow transplanta#on Blockade of ac#va#on of alloreac#ve T cells •  Dele#on of alloreac#ve clones •  Immunodevia#on: Th1 à༎ Th2 •  Regulatory T cells: –  CD4+CD25+ Treg: •  •  •  •  Naturally occurring or induced Foxp3+ Deple#on of Treg accelerate rejec#on Likely inhibit capacity of APC to ac#vate T cells –  CD8+ CD28- Treg: •  anergic phenotype •  not cytotoxic against donor cells •  CD94hi –  Increasing Treg numbers decrease GVHD •  Accommoda#on = a state of decreased alloreac#vity with #me a;er transplant. Unknown mechanism, likely mul#factorial •  Pigs as poten#al organ donors to increase organ supply •  Xenogra;s are rejected hyperacutely due to the presence of IgM an#- α- gal in humans (α- gal is expressed in the pig endothelial cells) •  Compounded with poor func#on of complement regulatory proteins (DAF, CD59, MCP) •  Gene#cally modified pigs have been generated (α- gal KO, DAF transgenic) •  Not clinically available •  Use of stem cell technology to regenerate damage #ssue: –  Mesenchymal stem cells have low immunogenicity –  Control of...
View Full Document

This note was uploaded on 09/23/2013 for the course MIMM 314 taught by Professor Rogerpalfree during the Winter '11 term at McGill.

Ask a homework question - tutors are online